Royal Bank Of Canada Metacrine, Inc. Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.35 - $0.46 $12 - $16	-35 Reduced 87.5%	5 $0
Q4 2021 Feb 14, 2022	SELL	$0.64 - $3.83 $1,795 - $10,746	-2,806 Reduced 98.59%	40 $0
Q3 2021 Nov 15, 2021	SELL	$2.61 - $3.84 $3,993 - $5,875	-1,530 Reduced 34.96%	2,846 $10,000
Q2 2021 Aug 16, 2021	BUY	$3.37 - $5.73 $14,747 - $25,074	4,376 New	4,376 $17,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.